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Abstract: Tau is a highly soluble protein mainly localized at a cytoplasmic level in the neuronal cells,
which plays a crucial role in the regulation of microtubule dynamic stability. Recent studies have
demonstrated that several factors, such as hyperphosphorylation or alterations of Tau metabolism,
may contribute to the pathological accumulation of protein aggregates, which can result in neuronal
death and the onset of a number of neurological disorders called Tauopathies. At present, there are
no available therapeutic remedies able to reduce Tau aggregation, nor are there any structural clues
or guidelines for the rational identification of compounds preventing the accumulation of protein
aggregates. To help identify the structural properties required for anti-Tau aggregation activity, we
performed extensive chemoinformatics analyses on a dataset of Tau ligands reported in ChEMBL. The
performed analyses allowed us to identify a set of molecular properties that are in common between
known active ligands. Moreover, extensive analyses of the fragment composition of reported ligands
led to the identification of chemical moieties and fragment combinations prevalent in the more active
compounds. Interestingly, many of these fragments were arranged in recurring frameworks, some of
which were clearly present in compounds currently under clinical investigation. This work represents
the first in-depth chemoinformatics study of the molecular properties, constituting fragments and
similarity profiles, of known Tau aggregation inhibitors. The datasets of compounds employed for
the analyses, the identified molecular fragments and their combinations are made publicly available
as supplementary material.
Keywords: Tau; tauopathies; Alzheimer’s Disease; chemoinformatics; ligand-based; molecular
descriptors; molecular fragments; drug repurposing; drug design
1. Introduction
Tauopathies are a class of heterogeneous neurodegenerative disorders generally char-
acterized by a progressive decline of cognitive functions, change in personality and memory
deficit in patients [1,2]. At present, more than twenty neurodegenerative disorders are
classified as tauopathies [3,4], the Alzheimer’s Disease (AD) being the most common [5,6].
A common hallmark characterizing these neurological disorders is the abnormal hyper-
phosphorylation and aggregation of the microtubule-associated protein (MAP) Tau in
neurofibrillary tangles (NFTs), especially within the neuronal and glia cells [7–9]. Tau
is a highly soluble protein, ubiquitously expressed in the human brain in six different
isoforms [10], which are normally associated with the microtubules (MTs) [11]. From a
structural viewpoint, four different regions have been identified in Tau, which belongs to
the class of intrinsically disordered proteins (IDPs) [12]. These include: (i) a N-terminal
region (NTR) that extends outwards when Tau binds to the MTs, thus regulating its dy-
namics; (ii) a microtubule-binding region (MBR) hosting the two well-known hexapeptide
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segments (i.e., PHF6 (VQIVYK) and PHF6* (VQIINK)) involved in the aggregation mech-
anisms [13,14]; (iii) a proline-rich region (PRR), and; (iv) a C-terminal region (CTR), the
latter two being highly conserved in mammals [15]. Under physiological conditions, Tau is
involved in the regulation of several signaling processes in cells through the interaction
with various binding partners [11,15–17]. Importantly, Tau participates in the regulation
of microtubules dynamic equilibrium [18] by stimulating tubulin assembly in neuronal
cells [19]. The mechanism by which Tau affects the correct physiological function of cells
in the brain has yet to be completely elucidated. However, it has been discovered that
its physiological function depends on the fine regulation of Tau phosphorylation and
dephosphorylation, which is operated by several different proteins in the brain [20]. Sev-
eral studies have demonstrated that the abnormal hyperphosphorylation, the presence
of mutations, and dysregulations in Tau splicing are among the most common causes of
tauopathies [15,21–23]. In particular, these studies have shown that hyperphosphorylated
Tau tends to dissociate from MTs, thus triggering a cascade of events that promote self-
aggregation into oligomers forming paired helical (PHF) and straight (SF) filaments. In
turn, the formation of such aggregates promotes their assembly into the neurofibrillary
tangles typically observed in brains of patients affected by tauopathies [21]. Moreover,
the accumulation of hyperphosphorylated Tau aggregates also leads to sequestration of
normal Tau and other MAP proteins [21], which are co-responsible for cellular toxicity.
Given the physio-pathological role of this protein in neurodegenerative disorders,
several efforts have been made to identify compounds able to disrupt Tau aggregation,
and thus restoring the normal physiological function of neurons and glia cells [24–26].
Notwithstanding, therapeutic remedies currently available for the treatment of tauopathies
are limited to amelioration or alleviation of symptoms [2,5]. Based on these premises,
the identification of drugs able to prevent or resolve the underlying causes of these neu-
rodegenerative diseases is of utmost importance, especially considering that tauopathies
mainly affect elderly people [5,6]. In this respect, several compounds able to modulate
Tau aggregation have been reported, most of them acting through non-covalent binding
mechanisms [25,27]. Moreover, different approaches have also been pursued to aid in
the identification of Tau anti-aggregating agents among natural products [28,29], which
represent a rich source of potential drug candidates [30,31]. In addition, inhibitors of
protein kinases as GSK-3 , PP2A, Fyn and CDK5, which indirectly regulate Tau phos-
phorylation levels, have been reported [32–34]. Furthermore, efforts for the identification
of chemical agents that prevent or abrogate Tau aggregation have also been recently
reported [32], aurones [35], diamino-phenothiazines [36], rhodanines [27], phenylthiazolyl-
hydrazides [27,37], N-Phenylamines, benzothizoles and polyphenols being among the most
studied chemical classes [38,39]. However, the majority of the identified ligands resulted
from independent screenings, often performed under different experimental conditions.
As such, structure-activity relationships (SAR) or pharmacophore requirements useful for
the identification of Tau aggregation inhibitors remain largely unknown. In this context,
the identification of key structural motifs and molecular properties required to achieve
high potency would significantly facilitate drug repurposing and/or the discovery of next
generation drug candidates.
Based on these premises, in this work we performed a series of chemoinformatics
investigations on ChEMBL [40], which included 2D similarity calculations, molecular
fragment analysis, and molecular descriptors evaluation, with the aim of identifying key
scaffolds, substructures, and molecular properties responsible for Tau activity. The analyses
allowed us to identify a set of chemical fragments, as well as combinations of molecular
properties that characterize potent Tau anti-aggregation inhibitors. Such information can
be used to assist in the rational design or repositioning of Tau aggregation inhibitors.
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2. Materials and Methods
2.1. Database Preparation
Tau aggregation inhibitors were collected from the ChEMBL database (accessed on
5 June 2020) [40] and filtered to retain only records with activity annotations related to
experiments on isolated protein, expressed in terms of Potency. In particular, only ac-
tivity records obtained through thioflavin T and S fluorescence assays on the human
microtubule-associated protein Tau (UniProt ID: P10636) were considered. Activity records
and compounds deriving from different experiments or from cell-based assays were re-
moved. Moreover, multiple activity annotations deriving from different experiments on the
same compound were also removed, retaining the one with the best value. This procedure
allowed us to obtain a total of 49,284 unique ligands, each associated with a single activity
annotation. The molecular structures and activity data of the filtered ligands were finally
stored as separated files and made available to readers as supplementary material (see
Supporting Information). All steps of ligand dataset generation were performed with the
KNIME software (version 4.3.2) [41].
2.2. 2D similarity Calculations
The 2D similarity degree of the filtered compounds was first assessed by means of
different molecular fingerprints, e.g., MACCS and ECFP4 from the OpenEye python toolk-
its [42], and AtomPairs and TopologicalTorsion from the RDKit libraries [43]. In particular,
all-vs-all similarity estimations were performed for compounds with Potency values be-
low 500 nM (905 compounds), for a total of around 820,000 comparisons. Moreover, the
similarity profile of these compounds was also evaluated with respect to those having
a reported Potency value higher than 1 µM (47,246 compounds). The 2D similarity was
evaluated in terms of the Tanimoto coefficient (Tc), by using default settings [44]. Moreover,
the similarity records obtained from the ECFP4 fingerprints-based estimations were further
analyzed to evaluate whether one or a selection of active ligands might be considered
as representative for the entire population of the most potent Tau aggregation inhibitors
considered in the analyses. In particular, extensive analyses were performed to identify
a set of compounds among the actives, that were able to retrieve at least 45 ligands with
an activity below 500 nM in the curated dataset (corresponding to ~5% of the total), and
according to commonly employed similarity thresholds [45]. The selected references were
also sequentially combined, up to a maximum of 20 queries per combination. This allowed
us to identify a set of active ligands, which were able to retrieve the highest number of
actives, while keeping the number of inactives low. For each combination, the percentage
of retrieved active and inactive ligands was evaluated, and the 20 best performing ones
were selected, along with their identified ligands, [45] to be further investigated. Moreover,
analysis of the similarity records obtained by ECFP4 fingerprints-based estimations was
also performed on the clustered dataset of ligands (see Supporting Information).
2.3. Analysis and Comparison of Molecular Descriptors
The molecular properties of the compounds under investigation were first analyzed
by using the QikProp software available in the Schrödinger suite (release 2020-1) [46],
with the default settings. To this aim, the compounds were prepared with LigPrep [47] to
calculate their ionization states and tautomers potentially present at physiological pH, and
to energetically minimize their structure. Then, around 50 molecular properties including
drug-likeness and blood-brain-barrier (BBB) permeability were calculated with QikProp
and compared with the corresponding property ranges of approved drugs.
An especially devised KNIME workflow was also developed to compare molecu-
lar properties of the active and inactive compounds in the curated dataset. To this end,
118 different molecular descriptors were first evaluated by using the RDKit nodes imple-
mented in KNIME [43]. Compounds were classified as “active” or “inactive” according to
their reported Potency values. In particular, ligands with Potency values below 500 nM
were considered as actives, while different activity thresholds (i.e.,  1 µM,  5 µM,  10 µM
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and  20 µM) were considered to classify ligands as “inactive”, these values being very
often used in chemoinformatics approaches to define inactivity. Statistical details of com-
pounds classified as inactive according to the various thresholds and types of activity are
reported in Table S1 (see Supporting Information). Afterwards, the molecular descriptors
of the “active” and “inactive” compounds that provided Pearson Correlation Coefficient
(PCC) values higher than 0.95 were removed, and statistical distributions of the others
were compared through the use of the one-sided Wilcoxon test [48]. This test has been
previously employed to evaluate statistical differences among the properties of populations
of ligands in chemoinformatics experiments [49,50], including those that are non-normally
distributed. The Bonferroni correction was applied to adjust the significance level (p-value)
of the analyses for multiple comparisons of the statistical tests [51]. Finally, the molecular
descriptors that resulted statistically different in the two populations were further evalu-
ated. This allowed us to highlight relevant differences in the molecular properties of the
active and inactive ligands at different thresholds of inactivity.
2.4. Molecular Fragment Analyses
An analysis of the molecular fragments characterizing the compounds in the prepared
database was also performed. To this aim, the collected compounds were first fragmented
by using an in house developed python script implemented with the RDKit libraries [43]
and the OpenEye toolkits [42]. Different types of fragmentation algorithms were used in the
analyses, including BRICS [52], Bemis-Murcko [53] and Recap [54]. Moreover, the Chomp
software (version 3.1.1.2—OpenEye) [55] was also used with default settings, as it allows to
generate molecular fragments according to the RLF chemical heuristics seek, which allows
to break all non-ring and non-resonance single bonds of a given molecule. Then, fragments
with a number of atoms outside the range of 5 to 55, and present in less than three molecules
were removed. Duplicate structures derived by fragmentation of different compounds
were also removed. The number of unique molecular fragments obtained for the active
and inactive Tau ligands is reported in Table S2. Afterwards, a workflow implemented in
KNIME (version 4.3.2) was devised to identify molecular fragments and their combinations
present only, or in common between, active and inactive Tau ligands. Molecular fragments
and their combinations generated in these analyses are made available as supplementary
material (see Supporting Information).
3. Results and Discussion
3.1. Dataset Preparation for the Analyses
A dataset of Tau ligands was first generated as detailed in Section 2. The selection
of Tau aggregation inhibitors was limited to compounds that were assayed under com-
parable experimental conditions, by selecting compounds tested with Thioflavin T and
S fluorescence assays (see Table S3). Although these assays can be performed in tandem
with other experiments (e.g., circular dichroism spectroscopy or microscopy, and atomic
force microscopy) [35,56,57], in order to circumvent potential false positive readouts, data
from the Thioflavin T and S fluorescence experiments provide a rich source of information
for chemoinformatics analyses and an appropriate statistical representation of the entire
population of Tau chemotypes. Indeed, the number of compounds that were not tested
with the Thioflavin T and S fluorescence assays was sensibly lower (see Table S1 in the
Supporting Information). Activity data distributions showed that more than 95% of the
reported ligands have Potency values above 1 µM (Figure 1), while less than 2% had values
below 500 nM. This data is of particular interest, considering that more than 100 chemo-
types were identified in the 0–500 nM activity range by visual inspection of their chemical
structures.
Of note, some of the molecules in the curated dataset have also been tested in different
types of assays, providing comparable results (e.g., see CHEMBL140 and CHEMBL191083
in [58,59]).
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In particular, the similarity analyses showed that the active compounds present high
diversity in terms of fragment composition (Figure 2). Indeed, the evaluated Tc values
according to MACCSfp were largely below the commonly reported similarity threshold
(less than 1% of all comparisons). On the contrary, a higher degree of similarity could be
observed in their connectivity tables, as more than 38% of the similarities evaluated with
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ECFP4 fingerprints provided Tc values above 0.3 [45]. Table 1 summarizes the number and
percentage of similar pairs identified among active compounds.
Table 1. Results of the similarity estimations performed in the curated dataset of Tau ligands. The similarity estimations




















MACCSfp 1859 0.5 27,604 0.1
ECFP4fp 159,125 38.8 13,460,261 30.8
AtomPairsfp 9093 2.2 488,407 1.1
TopologicalTorsionfp 42,477 10.4 2,670,815 6.1
1 Similarity thresholds were taken from [45] for MACCS and ECFP4, and from [60] for AtomPairs and TopologicalTorsion fingerprints.
2 The total numbers of active and inactive compounds considered in the analyses are 905 and 47,246, respectively. 3 The total number of
comparisons performed by considering only active compounds are 409,965, which became 43,733,220 by including also inactive ligands.
According to the performed similarity estimations, different results were observed
by using AtomPairs and TopologicalTorsion fingerprints, which evaluate chemical simi-
larity in terms of atom-based and consecutive non-hydrogen bond environments, respec-
tively [61,62]. Indeed, the percentages of similarity revealed by these fingerprints were
2.2% (AtomPairs) and 10.4% (TopologicalTorsion), these values being calculated according
to the thresholds for randomness (95% level) suggested in the RDKit documentation [60].
Overall, this analysis highlighted a low degree of similarity between the curated dataset
of the Tau active compounds, which mostly originates from their different fragment and
chemotype composition. The adopted fingerprints provided a different performance in
identifying pairs of similar ligands, the highest numbers of associations being observed
for ECFP4fp and TopologicalTorsionfp also in consensus screenings (Table S4). Of note,
ECFP4fp showed the best performance in retrieving active compounds (Table 1). How-
ever, ECFP4fp fingerprints yielded the highest number of comparisons above the selected
threshold of similarity (30.8% of the total) when inactive ligands were also included in the
similarity analyses (Table 1). Consequently, using ECPF4fp in a virtual screening protocol
could potentially increase the number of false positives; therefore, the integration with
other methods should be carefully evaluated.
The fact that ECFP4fp provided the highest number of similarities suggests that this
type of fingerprint was able to more efficiently identify common structural patterns among
active ligands. Such a feature might be of interest, for example, for the selection of repre-
sentative queries in a virtual screening. Indeed, an analysis of the ECFP4fp-based similarity
records showed that CHEMBL1558683 was able to retrieve up to 10% of the active ligands,
the statistics of the best performing compounds being reported in Table S5. Different
results were observed when inactive compounds were also considered in the similarity
analyses. In this case, the highest difference in the percentage of retrieved active vs. inactive
ligands was obtained for CHEMBL1555206. Although the best performing compounds
were able to retrieve a reasonable number of active ligands, their screening performance
was not satisfactory. Indeed, the observed enrichment factors (EF), the area under the
curve (AUC) and the BEDROC values were, on average, below the performances desir-
able in virtual screenings [63,64]. The best AUC and BEDROC values were observed
for CHEMBL1512606 (AUC ~0.7) and CHEMBL1377126 (BEDROC ~0.38), respectively.
To further evaluate whether the common structural patterns observed in the previous
ECFP4fp-based analyses might be due to the observed high degree of similarity among
small subsets of active ligands, clustering analyses were also performed. In particular,
different datasets including active and inactive ligands at different thresholds of inactivity
(i.e.,  1 µM,  5 µM,  10 µM and  20 µM) were first clustered with Canvas (Schrödinger
suite 2020-1) [65], as described in the Supporting Information. Then, the ability of the
active compounds in each of the generated clusters in retrieving actives and inactives was
evaluated. Interesting results were obtained for clusters identified from the datasets of
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the most potent Tau aggregation inhibitors and ligands with a reported Potency value
above 10 µM or 20 µM. Indeed, the majority of them presented at least an active compound
showing satisfactory AUC and EF values (Table S6), while poorer prediction performances
were obtained for clusters defined by activity thresholds of  1 µM and  5 µM (Table S6).
This result is indicative of the presence of a high number of common structural patterns
between small subsets of active ligands, in line with the previously observed chemotype
variability.
These results prompted us to also evaluate whether a combination of ligands would
be able to more efficiently represent the population of the active compounds in the dataset.
To this aim, the similarity data obtained from the ECFP4fp-based analyses (see Section 2.2)
were further processed, combining the records of the best performing compounds, up to
a maximum of twenty ligands per combination. For each combination we evaluated the
percentages of retrieved active and inactive ligands (see Table 2). The list of reference com-
pounds in the identified combinations is reported in Table S7. The identified combinations
of references allowed us to retrieve up to one third of the actives in the curated dataset.
The best results were obtained for the combination of 20 queries, both in terms of higher
number of actives, and greater difference between the percentages of active and inactive
ligands retrieved by the similarity records.
Table 2. Percentages of active and inactive ligands retrieved by the best performing combinations of









% of Actives and
Inactives 2
1 10.8 (98) 3.2 (1568) 7.6 (16)
2 18.1 (164) 5.1 (2465) 13.0 (15)
3 22.4 (203) 6.6 (3189) 15.8 (16)
4 24.2 (219) 6.7 (3238) 17.5 (15)
5 28.3 (256) 9.5 (4591) 18.8 (18)
6 30.1 (272) 10.5 (5074) 19.6 (19)
7 32.7 (296) 12.3 (5944) 20.4 (20)
8 32.2 (291) 12.1 (5847) 20.1 (20)
9 33.7 (305) 13.6 (6572) 20.1 (22)
10 33.8 (306) 13.9 (6717) 19.9 (22)
11 32.9 (298) 12.9 (6234) 20.0 (21)
12 33.7 (305) 13.3 (6427) 20.4 (21)
13 35.0 (317) 14.3 (6910) 20.7 (22)
14 35.0 (317) 14.4 (6959) 20.6 (22)
15 35.1 (318) 14.5 (7007) 20.6 (22)
16 35.7 (323) 14.8 (7152) 20.9 (22)
17 36.8 (333) 15.7 (7587) 21.1 (23)
18 36.8 (333) 15.7 (7587) 21.1 (23)
19 36.8 (333) 15.6 (7539) 21.2 (23)
20 37.1 (336) 15.9 (7684) 21.2 (23)
1 The number of compounds retrieved by the combination of references is reported in round brackets. 2 The
number of inactives per active compound is reported in round brackets. The total numbers of active and inactive
compounds are 905 and 47,246, respectively.
As shown in Table 2 and Figure S1, the rate of retrieved actives per number of queries
grows higher than that of the inactives, for combinations of one to seven references. In
contrast, the number of actives retrieved by combinations of ten or more queries remained
more or less stable. However, results reported in Table S7 showed that the use of combi-
nations of queries still provided poor discriminating performances according to the AUC
and BEDROC indexes. Overall, although the use of combinations of queries increased
the number of retrieved active compounds, their prediction performances were still not
satisfactory. Altogether, results of the similarity analyses did not allow the identification of
compounds (or combinations thereof) to be used as representatives of the entire popula-
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tion of actives, or able to discriminate actives from inactives. Instead, results implied the
presence of a number of small groups of highly structurally similar ligands in the analyzed
dataset, suggesting that 2D similarity estimations alone might not be an ideal method to
perform, for example, virtual screening on this target.
3.3. Analysis and Comparison of Molecular Descriptors
The compounds were then evaluated for their drug-like properties and blood-brain-
barrier (BBB) permeability. This analysis was performed by means of the QikProp software
available in the Schrödinger suite (release 2020-1) [46,47]. The results showed that the
majority of the compounds present good drug-like properties and are able to cross the
BBB, such prediction being especially true for compounds with activity below 500 nM. The
results of this analysis are reported in Table S8.
Extensive in silico analyses were then performed to evaluate whether the active and
inactive compounds present statistically different molecular properties. The analyses were
performed on different populations of inactive ligands, i.e., by considering  1 µM,  5 µM,
 10 µM and  20 µM inactivity thresholds, and by using the 118 molecular descriptors
implemented in the “RDKit Descriptor Calculation” node available in KNIME. Molecular
descriptors with PCC   0.95 were removed to avoid potential inter-correlation issues.
Then, a statistical comparison of the remaining molecular descriptors was performed
through a one-sided Wilcoxon test, to evaluate whether the mean values in the actives and
inactives datasets were statistically different. The results, shown in Figure 3 and Figure S2,
demonstrate that 41 of the calculated molecular descriptors provided statistically different
results (see Table S9), although none of them alone was able to clearly separate actives
from inactives (see Table S10). These results are likely due to the high molecular diversity
observed in the dataset.
Interestingly, these analyses allowed us to delineate a set of molecular properties that
should be present in active compounds.
In particular, the introduction of aryl-substituted H-bond acceptors is generally fa-
vored. Indeed, the NumAmideBonds and NumHBA descriptors were on average higher for
the active compounds. Moreover, active compounds had a higher number of aromatic
and heteroaromatic rings compared to the inactives (on average from 2 to 4 and up to 2,
respectively). Also, the presence of aliphatic moieties is associated with inactivity, as
highlighted by the lower values of the NumAliphaticHeterocycles, NumAliphaticRings and
NumSaturatedHeterocycles molecular descriptors in the active compounds. Consistently, the
NumSaturatedRings of inactive compounds was lower at 5 µM, 10 µM and 20 µM inactivity
thresholds. Together, these results suggest that an increase of the aliphatic character of the
molecules result in a decrease of activity. Moreover, it also suggests that aromatic com-
pounds able to establish ⇡–⇡ interactions may more efficiently interact with Tau. The active
compounds had, on average, higher values of logP (Table S10). Active and inactive com-
pounds also differ for their atomic valence connectivity indexes, which tend to be higher for
the former class (e.g., Chi0v, Chi3n and Kappa 2) [66]. Moreover, higher values of MOE-type
descriptors related to the surface area with partial charges (e.g., PEOE_VSA1,3,7,11,12,13),
molar refractivity (e.g., SMR_VSA1,3,9) and LogP (e.g., SlogP_VSA1,6,8,11) were also observed
for the more active compounds [66,67]. Finally, topological descriptors based on the count
of simple structural features, i.e., cyclic divalent nodes (MQN30) and 6-membered rings
(MQN36) [68], were higher for the active compounds. In conclusion, the analysis of molecu-
lar descriptors provided some hints on molecular properties that active compounds should
possess, which could be useful for drug design.
Molecules 2021, 26, 5039 9 of 15Molecules 2021, 26, x FOR PEER REVIEW  9 of 15 
 
 
Molecules 2021, 26, x. https://doi.org/10.3390/xxxxx www.mdpi.com/journal/molecules 
 
Figure 3. Distribution plot of statistically different molecular descriptors. Each distribution is represented by means of its negative logarithmic p-value of the one-sided Wilcoxon test. 
The Bonferroni threshold, which is displayed as a blue line, highlights the adjusted significance level (p-value) for multiple comparisons at statistical tests. Molecular descriptors 
marked with “^” are those whose values are on average lower for the inactive compounds with respect to the actives. Molecular descriptors marked as “**” present values that are, on 
average, higher for the active compounds, with respect to inactives at 1 µM, 5 µM and 10 µM activity thresholds. Molecular descriptors that are marked with “^^” present values that 
are, on average, higher for the active compounds, with respect to inactives at 5 µM, 10 µM and 20 µM activity thresholds. 
Figure 3. Distribution plot of statistically differ nt molecular descriptors. Each distribution is represented by means of its negative logarithmic p-value of the one-sided Wilcoxon test. The
Bonferr i threshold, which is d splayed as a blue line, highlights t e adjus ed significance level (p-value) for multiple comparisons at statistical e s. Molecular descriptors marked with
“ˆ” re those whose values are on averag lower for the inactiv compounds with respect to the actives. Molecular descriptors marked as “**” present values that are, on average, higher for
the active compounds, with respect to i actives at 1 µM, 5 µM and 10 µM activity thresholds. Molecular descriptors that are marked with “ˆˆ” present values that are, on average, higher
for the active compounds, with respect to inactives at 5 µM, 10 µM and 20 µM activity thresholds.
Molecules 2021, 26, 5039 10 of 15
3.4. Analysis of Molecular Fragments
An analysis of the molecular fragment composition for compounds in the curated
dataset was also performed. Fragmentation was performed by means of five different
algorithms. This allowed us to exhaustively identify chemical moieties and functional
groups present in Tau active and/or inactive compounds at different thresholds of inactivity.
In particular, we were able to identify 38 chemical moieties exclusively present in the
active ligands (Table S11), and 70,330, 63,678, 57,407 and 25,637 molecular fragments
present only in the inactives at 1 µM, 5 µM, 10 µM and 20 µM thresholds of inactivity,
respectively. Statistics related to the identified fragments are reported in Table S12. Visual
inspection of the molecular fragments of active compounds revealed the presence of at
least one hydrogen bond acceptor group. Moreover, around 50% of them had also one
or more aromatic or heteroaromatic ring(s), often bonded together or through carbonyl
and/or linear alkenes linkers. A high number of fragments in common between the
active and inactive sets have also been detected. However, also in this case, aromatic and
heteroaromatic groups and fragments bearing H-bond acceptors were generally prevalent
in the active compounds (Table S12). On the contrary, molecular fragments with hydrophilic
rings, such as piperazine and morpholine, or saturated rings, were more present in the
inactive compounds. A list of the more frequently observed molecular fragments is reported
in Table S13, along with their percentages of occurrence in the active and inactive sets.
Altogether, these results suggest that aromatic/heteroaromatic fragments and H-bond
acceptors are expected to contribute favorably to activity, as opposed to hydrophilic or
saturated chemical moieties. The complete list of molecular fragments identified in the
analysis is provided as supplementary material (see Supporting Information). Interestingly,
we also found that certain combinations of molecular fragments are especially present in the
active dataset (Table S14). These include the combination of 2 or 3 molecular fragments, for
example the phenyl and carbonyl groups with fragments bearing other H-bond acceptors,
which were present in more than 32% and 16% of the active compounds, respectively (see
Table S14, sections A and B). The combinations of molecular fragments identified in active
compounds are provided as supplementary material (see Supporting Information). Of
note, visual inspection of the more frequent fragment combinations revealed that active
compounds are often organized into molecular frameworks composed by two aromatic
or heteroaromatic rings separated by different 2- to 7-atom linkers. This latter moiety is
very often decorated with H-bond acceptors or may consist of rigid linear unsaturated
functional groups (Figure 4).
Notably, the identified framework is present in some of the already reported Tau-
based drug candidates currently undergoing clinical trials (e.g., xalsalate and curcumin)
(Figure S3) [69,70], as well as in the natural compounds xanthohumol and licochalcone
A that act as Tau aggregation inhibitors [70,71] (Figure S3). The latter chemotype is cur-
rently under evaluation on several targets related to neurodegenerative diseases, includ-
ing monoaminoxidase B, ↵ -amyloid and ↵-sinuclein [72–74]. These findings further
strengthen the potential use of molecular fragment combinations based on this framework
as starting points for the development of novel Tau aggregation inhibitors.
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4. Conclusions
In this work, we have reported the first extensive chemoinformatics study on Tau
ligands that systematically analyzed the similarity profiles, molecular properties and chem-
ical fragments of a large dataset of compounds with known activity on Tau aggregation.
In particular, similarity estimations were performed by means of different types of fin-
gerprints, identifying a high degree of structural diversity. Comparison of the molecular
properties of active and inactive compounds confirmed the presence of significant struc-
tural diversity and allowed us to outline a set of molecular properties that compounds
should possess in order to display high potency. A comparative analysis of the molecular
fragments of Tau ligands corroborated the results obtained with the molecular descrip-
tors and brought attention to the need for aromatic/heteroaromatic rings an hydrogen
bo acceptor , as opposed to hydrophilic or saturated chemical moieties. Notably, an
analysis of fragment combinations showed that active compounds re of en organized into
molecular frameworks composed by two aromatic or heteroarom tic rings s parated by
differ nt 2- to 7-atom li kers, the latter moiety being very often decor ted with H-bond
acceptors or possibly consisting of rigid linear unsaturated functional groups. Altogether,
the results of this study sho e the possibility to identify a set of molecular properties
and fragment combinations that can be useful for de novo drug design or drug repurposing
campaigns.
Supplementary Materials: The following are available online, Figure S1: Percentages of active and
inactive compounds retrieved by means of the selected query combinations.; Figure S2: Distribution
plots of the molecular descriptors compared in the analyses.; Figure S3: Chemical structures of the
xalsalate, curcumin, xanthohumol and licochalcone A known Tau aggregation inhibitors.; Table S1:
Number of ligands according to different activity thresholds and type.; Table S2: Number of unique
molecular fragments identified from the analyses of the active and inactive datasets.; Table S3: Assay
types and description related to the compounds considered in this work.; Table S4: Statistics related
to the combinations of the different fingerprints employed in the similarity estimations.; Table S5:
Percentages of actives and inactive ligands retrieved by the best performing queries, according to the
ECFP4fp similarity estimations.; Table S6: Best-three performing queries identified for each cluster in
the different datasets of ligands.; Table S7: Results of the ECFP4fp-based similarity screenings obtained
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for the best performing set of queries per combination.; Table S8: Percentages of Tau aggregation
inhibitors that present good drug-like properties according to commonly recommended values, as
evaluated with QikProp (Schrödinger 2020-1).; Table S9: Mean (±Standard deviation), and 10th
and 90th percentiles evaluated for the molecular descriptors that emerged as different for the active
and inactive compounds.; Table S10: Percentage of compounds with molecular descriptors within
the 10th and 90th percentile thresholds of the active compounds.; Table S11: Molecular fragments
observed exclusively in the active compounds.; Table S12: Statistics related to molecular fragments
identified in the active and inactive datasets.; Table S13: Molecular fragments that provided the
larger difference in their prevalence across the active and inactive classes.; Table S14: Combinations
of fragments more frequently observed in the active ligands, according to percentages of occurrence.;
Ligands clustering; The datasets of compounds employed for the analyses, the molecular fragments
and their combinations identified are provided as supplementary material.
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